Capital Asset Advisory Services LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Capital Asset Advisory Services LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 19.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,145 shares of the biopharmaceutical company’s stock after purchasing an additional 14,492 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Pfizer were worth $2,323,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Mather Group LLC. increased its position in shares of Pfizer by 35.0% during the third quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock valued at $1,133,000 after acquiring an additional 8,857 shares during the last quarter. Samalin Investment Counsel LLC increased its position in shares of Pfizer by 8.2% during the third quarter. Samalin Investment Counsel LLC now owns 11,312 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 862 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Pfizer by 97.8% during the third quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock valued at $6,097,000 after acquiring an additional 90,896 shares during the last quarter. Staley Capital Advisers Inc. increased its position in shares of Pfizer by 4.3% during the third quarter. Staley Capital Advisers Inc. now owns 1,346,187 shares of the biopharmaceutical company’s stock valued at $44,653,000 after acquiring an additional 55,290 shares during the last quarter. Finally, Bank of Nova Scotia increased its position in Pfizer by 219.4% in the third quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock worth $182,567,000 after buying an additional 3,780,696 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Trading Up 0.7 %

Shares of PFE traded up $0.19 during trading hours on Friday, hitting $27.99. The company had a trading volume of 33,161,255 shares, compared to its average volume of 40,908,660. The firm has a market cap of $158.61 billion, a P/E ratio of -467.09, a P/E/G ratio of 1.08 and a beta of 0.70. The stock’s 50 day moving average price is $27.81 and its 200 day moving average price is $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.